Trial · NCT07913243
Small Monetary Incentives for Digital Cognitive Training Adherence in Community-Dwelling Older Adults
NCT07913243, Not applicable, Not yet recruiting, Xuanwu Hospital, Beijing
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Small Monetary Incentives for Digital Cognitive Training Adherence in Community-Dwelling Older Adults. Trials, record NCT07913243. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913243
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Small Monetary Incentives for Digital Cognitive Training Adherence in Community-Dwelling Older Adults
- NCT number
- NCT07913243
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Xuanwu Hospital, Beijing
- Conditions
- Cognitive Decline, Dementia Prevention
- Interventions
- Digital cognitive training, Monetary incentive 0.2 CNY/day, Monetary incentive 0.5 CNY/day, Monetary incentive 1 CNY/day
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adherence Rate to Digital Cognitive Training During the Intervention Period | Weeks 2-13 (84 days) | The primary outcome is the completion rate of digital cognitive training during the 12-week intervention period (Weeks 2-13, 84 days). Completion rate is defined as the number of days on which all prescribed training tasks were completed divided by 84 days, multiplied by 100%. Participants who withdraw or do not train on a given day are counted as non-adherent, with the denominator remaining 84 days. The primary comparison is between the combined incentive groups and the control group. |
| Secondary | Stage-Specific Completion Rate of Digital Cognitive Training | Week 1; Weeks 2-13; Weeks 14-17 | Completion rate calculated separately for the run-in period (Week 1, 7 days), intervention period (Weeks 2-13, 84 days), and follow-up period (Weeks 14-17, 28 days). For each stage, completion rate = number of days with all prescribed tasks completed / total days in that stage × 100%. |
| Secondary | Stage-Specific Participation Rate | Week 1; Weeks 2-13; Weeks 14-17 | Participation rate calculated separately for the run-in, intervention, and follow-up periods. Participation rate = number of days with APP login and at least 1 completed training task / total days in that stage × 100%. This distinguishes "starting training" from "completing all tasks". |
| Secondary | Mean Daily Number of Training Tasks Completed | Week 1; Weeks 2-13; Weeks 14-17 | Average number of training tasks completed per day during the run-in, intervention, and follow-up periods, recorded automatically by the APP. This reflects training dose. |
| Secondary | Weekly Trend in Mean Daily Training Tasks | Weeks 1-17 (weekly) | Weekly average number of daily training tasks from Week 1 to Week 17, analyzed using a linear mixed model to assess changes over time and differences between groups. Used to evaluate whether incentive effects decay and how training behavior changes after incentive withdrawal. |
| Secondary | Change in Montreal Cognitive Assessment (MoCA) Score | Baseline; Week 14 | Change in MoCA total score from baseline to post-intervention (Week 14). MoCA score ranges from 0 to 30, with higher scores indicating better cognitive function. Administered on-site by trained researchers using a standardized protocol. |
| Secondary | Change in DiaMem Score | Baseline; Week 14 | Change in DiaMem score from baseline to post-intervention (Week 14). DiaMem score is the mean of three tests (one on-site and two home-based), ranging from 0 to 100. Higher scores indicate better cognitive function. |
| Secondary | Proportion of Participants Achieving High Adherence (≥80%) | Weeks 2-13 | Proportion of participants in each group with an intervention-period completion rate ≥80%. Numerator: number of participants with completion rate ≥80%; denominator: number of randomized participants who did not withdraw informed consent. |
| Secondary | Recruitment Rate | Recruitment period | Proportion of older adults in the target community who actively contacted the researcher, underwent preliminary screening, signed informed consent, and successfully downloaded the cognitive training APP. Numerator: number of such participants; denominator: total number of age-eligible (≥60 years) smartphone-using older adults in the community during the same period. |
| Secondary | Run-in Completion Rate | End of Week 1 | Proportion of participants who passed the 1-week run-in and could independently complete at least 2 days of cognitive training. Numerator: number of such participants; denominator: all participants who signed informed consent and downloaded the APP. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913243
GET https://conductscience.org/api/trials/v1/NCT07913243/registered